# Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response

> **NCT04936971** · PHASE4 · WITHDRAWN · sponsor: **Edoardo Melilli**

## Conditions studied

- Kidney Transplantation
- Cytomegalovirus Infections

## Interventions

- **DRUG:** Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
- **OTHER:** no intervention

## Key facts

- **NCT ID:** NCT04936971
- **Lead sponsor:** Edoardo Melilli
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Impossibility to perform tests (elispot) of the study due to change of location of laboratory
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04936971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04936971, "Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04936971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*